- Home
- ATYR vs SPOK Comparison
ATYR vs SPOK Comparison
Compare ATYR & SPOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- SPOK
- Stock Information
- Founded
- ATYR 2005
- SPOK 2004
- Country
- ATYR United States
- SPOK United States
- Employees
- ATYR N/A
- SPOK N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- SPOK Telecommunications Equipment
- Sector
- ATYR Health Care
- SPOK Telecommunications
- Exchange
- ATYR Nasdaq
- SPOK Nasdaq
- Market Cap
- ATYR 330.7M
- SPOK N/A
- IPO Year
- ATYR 2015
- SPOK 1992
- Fundamental
- Price
- ATYR $3.68
- SPOK $15.89
- Analyst Decision
- ATYR Strong Buy
- SPOK Hold
- Analyst Count
- ATYR 6
- SPOK 1
- Target Price
- ATYR $18.60
- SPOK $15.00
- AVG Volume (30 Days)
- ATYR 1.9M
- SPOK 155.3K
- Earning Date
- ATYR 03-13-2025
- SPOK 04-30-2025
- Dividend Yield
- ATYR N/A
- SPOK 7.85%
- EPS Growth
- ATYR N/A
- SPOK N/A
- EPS
- ATYR N/A
- SPOK 0.73
- Revenue
- ATYR $235,000.00
- SPOK $137,653,000.00
- Revenue This Year
- ATYR $1,387.23
- SPOK $3.51
- Revenue Next Year
- ATYR $873.22
- SPOK N/A
- P/E Ratio
- ATYR N/A
- SPOK $21.82
- Revenue Growth
- ATYR N/A
- SPOK N/A
- 52 Week Low
- ATYR $1.42
- SPOK $13.24
- 52 Week High
- ATYR $4.66
- SPOK $17.96
- Technical
- Relative Strength Index (RSI)
- ATYR 50.20
- SPOK 40.62
- Support Level
- ATYR $2.98
- SPOK $15.70
- Resistance Level
- ATYR $4.32
- SPOK $16.86
- Average True Range (ATR)
- ATYR 0.36
- SPOK 0.38
- MACD
- ATYR 0.03
- SPOK -0.07
- Stochastic Oscillator
- ATYR 60.37
- SPOK 27.61
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.